Test Price
2,800 AED✅ Home Collection Available
C2CD3 Gene Orofaciodigital Syndrome Type 14 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This next-generation sequencing diagnostic test delivers 99.9% sensitivity for detecting C2CD3 gene mutations linked to Orofaciodigital Syndrome Type 14. Backed by ISO-accredited processing, the test includes VIP mobile phlebotomy with a temperature-controlled cold-chain home collection service available daily from 8 AM to 11 PM, and telephonic post-test clinical guidance for result interpretation.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The C2CD3 Genetic Test specifically targets mutations in the C2CD3 gene causing Orofaciodigital Syndrome Type 14 (OFD14), a rare congenital disorder affecting facial structures, oral cavity, and digits. This next‑generation sequencing assay ensures comprehensive coding‑region coverage with clinical‑grade accuracy, empowering precise diagnosis and genetic counseling.
| Feature | Our Test (NGS) | Sanger Sequencing Alternative |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – high‑throughput, simultaneous analysis of all coding regions | Single‑gene Sanger – sequential exon‑by‑exon analysis |
| Detection Sensitivity | >99.9% for point mutations, indels, and copy‑number variants | ~99% for point mutations only; may miss large deletions |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Precision | Clinically validated, ISO‑accredited laboratory | May require multiple runs, higher cost |
Physician Insight & Safety Protocols
As a Consultant Medical Genetics, I understand the importance of a definitive molecular diagnosis for rare syndromes like OFD14. This NGS‑based C2CD3 test offers the accuracy families need, but it must always be interpreted alongside a thorough clinical evaluation. Always consult your physician before making any changes to prescribed treatments.
Advisory: Medication and Treatment Continuity
Do not discontinue any prescribed medication or therapy without prior consultation with your treating physician. Sudden cessation may lead to serious health complications.
Safety Exclusion Criteria & Emergency Red Flags
- Patient inability to provide a blood sample (e.g., severe coagulopathy, active infection at venipuncture site).
- Incomplete or contradictory clinical history that may delay accurate result interpretation.
- Seek immediate medical attention if the patient experiences acute respiratory distress, cyanosis, or uncontrolled seizures – these must be stabilized before any elective genetic testing.
Patient FAQ & Clinical Guidance
1. What does the C2CD3 gene test reveal for my child?
The C2CD3 NGS test identifies pathogenic variants responsible for Orofaciodigital Syndrome Type 14, clarifying the genetic cause of facial, oral, and digital malformations.
2. Who should consider this test?
Individuals with clinical features such as midline cleft lip, lingual hamartomas, or digital anomalies, and families with a history of syndromic congenital conditions, benefit most from diagnostic sequencing.
3. How is the test performed and when will results be available?
A simple blood draw or a dried blood spot collected at home by VIP mobile phlebotomy provides sufficient DNA; NGS results are issued within 3 to 4 weeks with comprehensive interpretation.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring encrypted storage and processing of all genomic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the secure handling of health information.
- ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139); DHA facility license 1143.
Clinical & Logistical Metadata
| Test Name | C2CD3 Gene Orofaciodigital Syndrome Type 14 Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood / Dried Blood Spot (DBS) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Q87.0 |
| LOINC Code | 95039-2 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians